Vladislav Sergeev
@AGCT_teamCell processing guy at RM Gorbacheva Memorial Research Institute, Pavlov University. All tweets are my own. Have fun guys!
Similar User
@AlbeenaDr
@MarcoRuella
@ferrari_sam93
@DermalCell
@MaxMamonkin
@PablixSil
@c_thieblemont
@aljurf100
@CChabannon
@VaroqueauxN
@_strangescience
@MalinHultcrantz
@OncoPolmoneIEO
@srqstockpicker
@AnnalisaRugger1
CD19 CAR-T Therapy is becoming a game changer for intractable CTD. #ACR24
iCell (CD19x BCMA CAR-T) has lower infections vs Teclistamab (BCMA TCE) cites lower infection cuz T-Cell and NK cell increase to compensate B-cell depletion. but TCE's use up T-cells, so this compensation might not happen and increase infections (vs CAR-T)
C-CAR168 as a Novel Anti-CD20/BCMA Bispecific Autologous CAR-T Therapy for the Treatment of Autoimmune Diseases #ACR24 #CAR-T #Autoimmune abelzeta.com/abelzeta-prese…
#ASH24 Stem Cell Boost for Immune Effector Cell Associated Hematotoxicity (ICAHT) post anti-BCMA CAR-T for MM. N=22; significant improvement in cytopenia at 3 and 6-month post CAR-T #mmsm #bmtsm @MeeraMohanMD @adsouza_md ash.confex.com/ash/2024/webpr…
Excited to start enrolling on this trail infusing mem-like NK cells via peritoneal route. First clinical trial of “memory like” natural killer cells in ovarian cancer opens at Dana-Farb - goo.gl/alerts/93ky15 #GoogleAlerts
NGS variants prior to CAR #ASH24: - 173 pts, 63% axi-cel - 43% had CH prior to CAR: 54% DNMT3A, 26% TP53 - 6% developed MN: 3-yr cumulative incidence of 11% with death from LBCL as competing risk - median time CAR to MN 25 mos - CH➡️late thrombocytopenia after CAR #lymsm #bmtsm
Another day, another #ATTR amyloidosis trial published in @NEJM! Exciting late-breaker @American_Heart #AHA24, looking at 1+ year data with #CRISPR gene editing by @intelliatx The bottom line is all good news – sustained #TTR reduction, positive clinical signals, promising…
Mosun-pola v R-pola R/R LBCL @JulioChavezMD #ASH24: - 80 pts, 35-39% prior CAR - M-pola better: ORR 78%/CR 58% (vs 50%/35%), mPFS NR vs 6.4 mos - M-pola mDOR NR (vs 10.1 mos) - same G3-4 AE in both arms; all CRS G1-2 Would love to see response/survival in CAR-exposed pts. #lymsm
Neoadjuvant nivolumab & relatlimab in locally advanced MSI CRC @NatureMedicine doi.org/10.1038/s41591… 🔎NICHE-3 phs 2 👉PR 97%, MPR 92%, pCR 68% 👉only one recurrence 👉Gr 3–4 irAEs 10% 💪Impressive, we need to find the most effective, least toxic combination @myESMO
Researchers led by Kole Roybal, PhD, Director of the PICI Center at @UCSF, (@roybal_lab) have developed SNIPR (synthetic intramembrane proteolysis receptor), which enables T cells to detect soluble tumor signals & activate selectively within tumors: nature.com/articles/s4158… (1/3)
Prophylactic IL-6 receptor blockade with tocilizumab may reduce severe CRS in axi-cel for LBCL, but it comes with a caution: it might increase both the incidence and severity of neurotoxicity. Read more: astctjournal.org/article/S2666-…
Clearance of p21 highly expressing senescent cells accelerates cutaneous wound healing nature.com/articles/s4358…
1/ This is the next chapter of a story about courageous patients and their families, of multidisciplinary teamwork, and hard-fought steps forward to effective therapy for #DIPG #DMG, a universally lethal cancer of the brain and spinal cord. 🧵nature.com/articles/s4158…
How engineered T cells are changing the face of autoimmune diseases via B cell depletion science.org/content/articl… @ScienceMagazine @NewsfromScience @jcouzin open-access
We've already seen remarkable results for lupus and other autoimmune diseases with CD19 B cell depletion therapy. Now add IgG4 related disease (which has no treatment) in a new randomized trial @NEJM nejm.org/doi/full/10.10…
We've already seen remarkable results for lupus and other autoimmune diseases with CD19 B cell depletion therapy. Now add IgG4 related disease (which has no treatment) in a new randomized trial @NEJM nejm.org/doi/full/10.10…
Glofi-pola R/R LBCL @DocHutchings #ASH24: - 129 pts, 34% HGBL, 22% prior CAR - ORR 80%, CR 62% (if prev CAR ORR 75%, CR 50%) - mPFS 12 mos, mOS 39 mos - CRS/ICANS almost all G1-2; 10 G5 AEs! mPFS in CAR-exposed pts? Good activity in R/R HGBL as well. #lymsm
Today we report in @NatureBiotech a system for the laboratory evolution of engineered virus-like particles (eVLPs) that enables the discovery of eVLP variants with desired properties, including improved production and delivery potency. 1/13 PDF: drive.google.com/file/d/1E6Nr86…
Cytopenias in BCMA CAR T: unraveling inflammatory mechanisms ow.ly/GmUk50U5uvO #InsideBloodAdvances #IBAs #immunobiologyandimmunotherapy #plasmacelldisorders
Engineered Packaging Cell Line for the Enhanced Production of Baboon-Enveloped Retroviral Vectors dlvr.it/TG9wSm #MTNA
Very interesting work showing Hepatocellular senescence results in senescence and dysfunction in other organs nature.com/articles/s4155…
United States Trends
- 1. Bengals 80,8 B posts
- 2. Chargers 70,4 B posts
- 3. McPherson 12,4 B posts
- 4. Joe Burrow 22 B posts
- 5. Herbert 35,7 B posts
- 6. #BaddiesMidwest 22,1 B posts
- 7. #BoltUp 5.693 posts
- 8. Zac Taylor 4.432 posts
- 9. #ช็อตฟีลMV 174 B posts
- 10. MILKLOVE SHOT FEEL 226 B posts
- 11. #CINvsLAC 10,6 B posts
- 12. WWIII 183 B posts
- 13. #SNFonNBC N/A
- 14. Dobbins 8.797 posts
- 15. 60 Minutes 33,7 B posts
- 16. Scotty 10,3 B posts
- 17. TAEYEON 36,3 B posts
- 18. Harbaugh 16,4 B posts
- 19. Ladd McConkey 2.662 posts
- 20. Money Mac N/A
Who to follow
-
Albeena Nisar
@AlbeenaDr -
Marco Ruella
@MarcoRuella -
Samuele Ferrari
@ferrari_sam93 -
Dermal Cell News
@DermalCell -
Max Mamonkin
@MaxMamonkin -
Pablo SilvaRodriguez
@PablixSil -
C. Thieblemont
@c_thieblemont -
Mahmoud Aljurf
@aljurf100 -
Christian Chabannon
@CChabannon -
VaroqueauxN
@VaroqueauxN -
Katy
@_strangescience -
Malin Hultcrantz MD PhD
@MalinHultcrantz -
OncoPolmoneIEO
@OncoPolmoneIEO -
Boaty McBoatface
@srqstockpicker -
Annalisa Ruggeri
@AnnalisaRugger1
Something went wrong.
Something went wrong.